NCT03674814 2026-03-31
Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer
University of Chicago
Phase 1 Completed
Clinical Trials
70 trialsNCT07428642 2026-03-18
PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.
First Affiliated Hospital of Wenzhou Medical University
Completed
NCT05700903 2026-03-02
ARCH
University of Colorado, Denver
Phase 4 Completed
NCT05730712 2026-02-06
Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer
Mayo Clinic
Phase 2 Completed
NCT03556904 2026-01-15
FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT03734653 2025-11-06
Testosterone Therapy in Castration Resistant Prostate Cancer
University of Colorado, Denver
Phase EARLY_PHASE1 Completed
NCT02203695 2025-10-28
Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT05081193 2025-09-22
Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT06312670 2025-05-29
Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT02278185 2025-05-11
Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer
University of Colorado, Denver
Phase 2 Completed
NCT04332744 2025-05-11
ZZ-First
MedSIR
Phase 2 Completed
NCT02339168 2025-05-01
Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer
University of California, Davis
Phase 1 Completed
NCT03314324 2025-04-17
ODENZA
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Completed
NCT02684227 2025-03-19
Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT05612880 2025-01-09
Physical Function During ARSI Treatment
UNC Lineberger Comprehensive Cancer Center
Completed
NCT02366494 2024-11-25
Micro RNAs to Predict Response to Androgen Deprivation Therapy
Medical College of Wisconsin
Completed
NCT02213107 2024-11-13
Enzalutamide & Dutasteride/Finasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer.
University of Rochester
Phase 2 Completed
NCT03207529 2024-10-10
Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT04207255 2024-09-25
Addition of Opaganib to Androgen Antagonists in Patients With mCRPC
Medical University of South Carolina
Phase 2 Completed
NCT02099864 2024-09-19
Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy
OHSU Knight Cancer Institute
Phase 2 Completed
NCT02689427 2024-09-19
Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03336983 2024-08-01
BonEnza
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Phase 2 Completed
NCT02676986 2024-07-05
ARB
Queen Mary University of London
Phase 2 Completed
NCT03927391 2024-06-12
REDOSE
Radboud University Medical Center
Phase 4 Completed
NCT02453009 2024-05-30
CHEIRON
Santa Chiara Hospital
Phase 2 Completed
NCT02555189 2024-05-13
Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression
Thomas Jefferson University
Phase 1/2 Completed
NCT02903160 2024-02-07
Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT03751436 2023-10-16
Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer
Roswell Park Cancer Institute
Phase 1 Completed
NCT02058706 2023-05-10
LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT02028988 2023-05-06
Enzalutamide + External Beam Rt For Prostate
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03310541 2023-05-06
AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT01974765 2023-04-28
Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03123978 2023-04-26
Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer
University of California, Davis
Phase 1 Completed
NCT04290611 2023-04-13
VENDY
Groupe Hospitalier Pitie-Salpetriere
Completed
NCT03464201 2023-02-22
GREKO III
Grupo Español de Tumores Huérfanos e Infrecuentes
Phase 2 Completed
NCT02833883 2023-01-19
Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT01942837 2022-10-24
Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02012296 2022-07-13
Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer
University of Chicago
Phase 1/2 Completed
NCT02090114 2022-06-27
Restore
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT02588001 2022-05-25
JCASTRE-Zero
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Phase NA Completed
NCT02268175 2022-04-19
Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03295565 2022-04-15
OSTRICh
The Netherlands Cancer Institute
Phase 2/3 Completed
NCT02814968 2022-04-14
PET/CT and WB MRI for Staging and Response in CRPC Patients Receiving Enzalutamide
The European Uro-Oncology Group
Phase 2 Completed
NCT02815033 2022-04-14
Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide
The European Uro-Oncology Group
Phase 2 Completed
NCT02601014 2022-02-03
STARVE-PC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT02207504 2022-01-06
Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT02346578 2021-09-16
Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy.
Osaka City University
Phase 2 Completed
NCT02138383 2021-08-17
Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02953860 2021-05-14
Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer
University of Colorado, Denver
Phase 2 Completed
NCT02125084 2021-05-04
Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer
SCRI Development Innovations, LLC
Phase 1 Completed